Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Clin Cancer Res. 2021 Oct 6;28(1):45–56. doi: 10.1158/1078-0432.CCR-21-2183

Figure 3.

Figure 3.

Clinical outcomes of patients treated with ibrutinib and buparlisib. A, Swim plot of 37 patients, 35 of whom were evaluable for response. Three patients with MCL proceeded to an allogeneic stem cell transplant while in remission. B, Waterfall plot using Lugano criteria. C, Progression-free survival in each disease cohort, showing median PFS of 33 months in MCL, 1.6 months in DLBCL, and 3.7 months in FL. D, Overall survival in each disease cohort. Median OS was 6.3 months in DLBCL, and not reached in MCL and FL.